ADVANTAGE MULTI FOR DOGS- imidacloprid, moxidectin solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

IMIDACLOPRID (UNII: 3BN7M937V8) (IMIDACLOPRID - UNII:3BN7M937V8), MOXIDECTIN (UNII: NGU5H31YO9) (MOXIDECTIN - UNII:NGU5H31YO9)

Available from:

Elanco US Inc.

Administration route:

TOPICAL

Prescription type:

PRESCRIPTION

Therapeutic indications:

Advantage Multi for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Advantage Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis ). Advantage Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. Advantage Multi for Dogs is also indicated for the treatment and control of the following intestinal parasites: Intestinal Parasite Intestinal Stage Adult Immature Adult Fourth Stage Larvae Hookworm Species Ancylostoma caninum X X X Uncinaria stenocephala X X X Roundworm Species Toxocara canis X X Toxascaris leonina X Whipworm Trichuris vulpis X Do not administer this product orally. (See WARNINGS.) Do not use this product (containing 2.5 % moxidectin) on cats.

Product summary:

Applications Per Package 6 x 0.4 mL tubes 6 x 1.0 mL tubes 6 x 2.5 mL tubes 6 x 4.0 mL tubes 6 x 5.0 mL tubes   90212430_PA505407X Revised: January 2023 Approved by FDA under NADA # 141-251 Made in Germany © 2023 Elanco or its affiliates. Advantage Multi, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Elanco TM Manufactured for: Elanco US Inc Greenfield, IN 46140 U.S.A.

Authorization status:

New Animal Drug Application

Summary of Product characteristics

ADVANTAGE MULTI FOR DOGS- IMIDACLOPRID, MOXIDECTIN SOLUTION
ELANCO US INC.
----------
_ELANCO_
ADVANTAGE MULTI™
FOR DOGS
(IMIDACLOPRID+MOXIDECTIN)
TOPICAL SOLUTION
ONCE-A-MONTH TOPICAL SOLUTION FOR THE PREVENTION OF HEARTWORM DISEASE,
THE
TREATMENT OF CIRCULATING MICROFILARIAE, KILLS ADULT FLEAS, IS
INDICATED FOR THE
TREATMENT OF FLEA INFESTATIONS, THE TREATMENT AND CONTROL OF SARCOPTIC
MANGE, AS WELL AS THE TREATMENT AND CONTROL OF INTESTINAL PARASITE
INFECTIONS
IN DOGS AND PUPPIES THAT ARE AT LEAST 7 WEEKS OF AGE AND THAT WEIGH AT
LEAST
3 LBS.
WARNING
• DO NOT ADMINISTER THIS PRODUCT ORALLY
• FOR THE FIRST 30 MINUTES AFTER APPLICATION ENSURE THAT DOGS CANNOT
LICK THE PRODUCT FROM APPLICATION SITES ON THEMSELVES OR OTHER TREATED
ANIMALS.
• CHILDREN SHOULD NOT COME IN CONTACT WITH APPLICATION SITES FOR TWO
(2) HOURS AFTER APPLICATION.
(SEE CONTRAINDICATIONS, WARNINGS, HUMAN WARNINGS, AND ADVERSE
REACTIONS, FOR MORE INFORMATION)
CAUTION:
Federal Law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION:
_Advantage Multi for Dogs_ (10 % imidacloprid + 2.5 % moxidectin) is a
colorless to yellow
ready-to-use solution packaged in single dose applicator tubes for
topical treatment of
dogs. The formulation and dosage schedule are designed to provide a
minimum of 4.5
mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin
based on body
weight.
Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The
chemical name for
imidacloprid is
1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine.
Moxidectin is
a semisynthetic macrocyclic lactone endectocide derived from the
actinomycete
_Streptomycetes cyaneogriseus noncyanogenus_. The chemical name for
moxidectin is
[6R, 23E, 25S(E)]-5-0-
Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-
(methoxyimino) milbemycin B.
TM
INDICATIONS:
_Advantage Multi for Dogs_ is indicated for the prevention of
heartworm disease caused
by _Dirofilaria immitis_ and the treatment of _Dirofilaria immitis_
circulating microfi